Gender affirming hormone therapy may be used to relieve dysphoria among transgender or gender-diverse individuals. However, the long-term effects of these treatments on reproductive health remain uncertain. Before initiating hormone therapy, it is essential that patients are fully informed about the potential impact on their reproductive capabilities. Fertility preservation options, such as oocyte cryopreservation, should be offered to gender diverse individuals who were assigned female at birth. To assist healthcare providers in navigating the complexities of fertility preservation for these patients, we conducted a SWOT (Strengths, Weaknesses, Opportunities, and Threats) analysis focused of oocyte cryopreservation. This analysis aims to ensure that decisions are both clinically sound and aligned with the patient's reproductive goals.